Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema

The purpose of this study is to compare the efficacy and assess the safety of CD07805/47 gel 0.5% applied topically once daily for 29 days versus vehicle control, in subjects with moderate to severe chronic persistent vascular facial erythema

Inclusion Criteria:

• Male or female, who is at least 18 years of age or older at screening visit.
• Presence of chronic persistent vascular facial erythema for ≥ 3 months by history.
• A Clinician's Erythema Assessment (CEA) score of ≥3 at Screening and at Pre-dose (T0) on Baseline/Day 1.
• A Patient Self Assessment (PSA) score of ≥3 at Screening and at Pre-dose (T0) on Baseline/Day 1.

Exclusion Criteria:

• More than 2 facial inflammatory lesions (papules, pustules, and nodules).
• Presence of areas of significant scaling or crusting on the face.
• Presence of psoriatic lesions on the face.
• Presence of any other dermatological condition of the face that, in the opinion of the Investigator, may significantly interfere with the interpretation of the clinical trial results.